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CurcuminGlomerulosclerosis and interstitial ﬁbrosis represent the key events in development of diabetic nephropathy
(DN), with connective tissue growth factor (CTGF), plasminogen activator inhibitor-1 (PAI-1) and ﬁbronectin 1
(FN-1) playing important roles in these pathogenic processes. To investigate whether the plant metabolite
curcumin,which exerts epigeneticmodulatory propertieswhen applied as a pharmacological agent,may prevent
DN via inhibition of the JNK pathway and epigenetic histone acetylation, diabetic and age-matched non-diabetic
controlmicewere administered a 3-month course of curcumin analogue (C66), c-Jun N-terminal kinase inhibitor
(JNKi, sp600125), or vehicle alone. At treatment end, half of the mice were sacriﬁced for analysis and the other
half were maintained without treatment for an additional 3 months. Renal JNK phosphorylation was found to
be signiﬁcantly increased in the vehicle-treated diabetic mice, but not the C66- and JNKi-treated diabetic mice,
at both the 3-month and 6-month time points. C66 and JNKi treatment also signiﬁcantly prevented diabetes-
induced renal ﬁbrosis and dysfunction. Diabetes-related increases in histone acetylation, histone acetyl
transferases' (HATs) activity, and the p300/CBP HAT expression were also signiﬁcantly attenuated by C66 or
JNKi treatment. Chromatin immunoprecipitation assays showed that C66 and JNKi treatments decreased H3-
lysine9/14-acetylation (H3K9/14Ac) level and p300/CBP occupancy at the CTGF, PAI-1 and FN-1 gene promoters.
Thus, C66 may signiﬁcantly and persistently prevent renal injury and dysfunction in diabetic mice via down-
regulation of diabetes-related JNK activation and consequent suppression of the diabetes-related increases in
HAT activity, p300/CBP expression, and histone acetylation.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Diabetic nephropathy (DN) is a common complication due to diabetes
and the most common cause of end-stage renal disease [1]. The patho-
genesis of DN involves genetic, environmental and hemodynamic chang-
es. These changes may cause oxidative stress and inﬂammation, which
leads to accumulation of extracellular matrix (ECM) proteins and renal
glomerulosclerosis (ﬁbrosis). Eventually glomerular dysfunction and
renal failure will occur [2–4]. It is known that pro-ﬁbrotic cytokinesUniversity, 218 Ziqiang Street,
86 431 88796975.
ital Research Institute at the
: +1 502 852 2214.
cai001@louisville.edu (L. Cai).(e.g. connective tissue growth factor (CTGF), plasminogen activator
inhibitor 1 (PAI-1), and ﬁbrotic cytokines ﬁbronectin 1 (FN-1)) play im-
portant roles in the development and progression of diabetic renal ﬁ-
brosis [5–7]. Understanding the exact mechanisms is needed for
developing novel therapeutic approaches to prevent renal ﬁbrosis.
The c-Jun N-terminal kinase (JNK) pathway mediates important
intracellular responses, such as cell growth and differentiation, and
cell death [8]. JNK proteins belong to the mitogen activated protein
kinase (MAPK) family. In the presence of oxidative stress and inﬂamma-
tion, the MAPK kinases, MKK4 and MKK7 activate JNK proteins via
phosphorylation [9]. The JNK pathway has been implicated in the devel-
opment of insulin resistance in obese and diabetic mice [10] and has
been shown to be activated signiﬁcantly in response to inﬂammatory
cytokines and oxidative stress in diabetic or high glucose conditions [11,
12]. Furthermore, a previous study demonstrated that the JNK pathway
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lation of FN-1 accumulation in renal interstitial ﬁbroblasts [13,14]. In
support of the theorized important role of JNK activation in DN, the
JNK speciﬁc inhibitor, SP600125, was shown to signiﬁcantly alleviate
the pathogenesis of DN [15].
Histone acetylation may be another mechanism involved in the eti-
ology of diabetes and the development of its complications [16]. Histone
modiﬁcation is a reversible dynamic process controlled by histone ace-
tyl transferase (HAT) and histone deacetylase (HDAC). These processes
regulate chromatin structure to facilitate or inhibit the transcription of
genes [17]. p300/CREB-binding protein (CBP) is an important HAT in di-
abetes. For example, p300 was shown to be up-regulated and histone
acetylationwas shown to be increased in the retina and heart of diabetic
animals [18]. Moreover, under high glucose conditions, p300 is induced
and histone acetylation is increased in endothelial cells, resulting in the
regulation of vasoactive factors and ECMproteins [19]. Activation of the
JNK pathway can also up-regulate p300 activity and histone acetylation,
thereby increasing the transcription of correlative genes [20], making
inhibition of p300 activity and histone acetylation a potential therapeu-
tic target for DN.
Curcumin has several known pharmacological effects, including anti-
inﬂammatory, anti-oxidative, and anti-ﬁbrosis [21–24]. Administration of
curcumin to diabetic animals effectively prevented high glucose- and
diabetes-induced oxidative stress in the endothelial cells and heart [25].
A clinical trial has demonstrated that dietary curcumin signiﬁcantly
prevented the pathogenesis and progression of diabetes and signiﬁcantly
reduced diabetic complications through its anti-inﬂammatory effects
[26]. In addition, the activation of the JNK pathway was down-regulated
by curcumin, which protected the kidney and heart from diabetes-
induced pathogenic changes [27]. Finally, curcumin speciﬁcally inhibits
p300. After curcumin treatment, p300 activity and histone acetylation
were decreased in monocytes grown in a high glucose environment,
ultimately leading to a decrease in pro-inﬂammatory cytokines [28].
Despite great therapeutic potential, the clinical efﬁcacy
of curcumin is limited by its low bioavailability [26,29]. Therefore,
we developed a curcumin analogue, C66 [(2E,6E)-2,6-bis(2-
(triﬂuoromethyl)benzylidene)cyclohexanone], which has the same
efﬁcacy at 50–200 fold lower doses as curcumin [30,31]. We
previously showed that C66 can signiﬁcantly inhibit high glucose-
induced MAPK phosphorylation and downstream inﬂammatory
responses in murine macrophages [30]. In the current study, we in-
vestigated whether C66 is able to prevent DN via suppression of
diabetes-induced JNK pathway activation, induction of p300/CBP
HAT activity, and histone hyperacetylation in the kidney. To this
end, we used the same samples from the animals that were used in
a related study that was recently published [32].
2. Materials and methods
2.1. Animals
The samples used in this study are the same as in our recently pub-
lished study [32]. Brieﬂy, 8–10 week old C57BL/6J male mice (Jackson
Laboratory, Bar Harbor, ME, USA) were housed in the University of
Louisville Research Resources Center at 22 °C with 12 h light/dark cy-
cles, and given free access to standard rodent chow and tap water. All
experimental procedures for the animal usage were in accordance
with the Guide for the Care and Use of Laboratory Animals andwere ap-
proved by the Institutional Animal Care and Use Committee of the Uni-
versity of Louisville.
The type 1 diabetesmousemodelwas inducedwith a single intraper-
itoneal injection of streptozotocin (STZ) (in sodium citrate, pH = 4.5;
Sigma-Aldrich, St. Louis, MO, USA) at 150 mg/kg; the aged-matched
non-modeledmice (control) were given the same volume of sodium cit-
rate buffer. Blood glucose was monitored on the 3rd day after injection,
and hyperglycemia (blood glucose levels ≥ 250 mg/dl) was noted inthe STZ-injectedmice. Both control and diabeticmicewere randomly di-
vided into the following three groups (n= 10 each): control group, C66
group, and JNKi (sp600125) group. These groupswere treated by gavage
with vehicle, C66 or JNKi (C66 and JNKi dissolved in 1% CMC-Na solu-
tion), respectively. All solutions were administered at 5 mg/kg, every
other day for 3 months. In a previous study, the JNKi was administered
at 30 mg/kg for short times [33], but we chose to administer it at a rela-
tively low dose to avoid any potential toxic effects of accumulated doses
of JNKi for the 3-month usage. At the end of the 3-month treatment, one
set of both diabetic and control mice (n = 4 or 5) from each group was
sacriﬁced and labeled as the 3-month study cohort. Another set of both
diabetic and control mice (n= 4 or 5) from each groupwas aged for ad-
ditional 3monthswithout further treatment and labeled as the 6-month
study cohort.
2.2. Renal function measurement
Spot urine and serum samples were collected immediately before
sacriﬁce. Commercial kits were used to measure urinary albumin
(Bethyl Laboratories, Montgomery, TX, USA) and urinary and serum
creatinine (BioAssay Systems, Hayward, CA, USA) concentrations. The
urinary albumin-to-creatinine ratio (ACR)was calculated as [urine albu-
min (μg/ml)] divided by [urine creatinine (mg/dl)] and presented as rel-
ative to values calculated for the control group.
2.3. Histopathological and immunoﬂuorescent staining
Kidney tissuewasﬁxed overnight in 10% phosphate-buffered forma-
lin, dehydrated in a graded alcohol series, cleared with xylene, embed-
ded in parafﬁn, and sectioned to 5 μm thickness. To examine overall
morphology, the parafﬁn sections were dewaxed for hematoxylin–
eosin (H&E) staining, as previously described [34], or with Masson's
trichrome, using the Sigma-Aldrich Trichrome Staining Kit. For immu-
noﬂuorescent staining, the parafﬁn-embedded kidney sectionswere in-
cubated with H3K9/14Ac primary antibody (1:2000; Cell Signaling
Technology, Danvers, MA, USA), after which sections were washed
with phosphate-buffered saline plus 0.1% Triton (PBS-T) (EM Science,
Hawthorne, NY, USA) and incubated with FITC-conjugated IgG second-
ary antibody (1:200; Abcam, Cambridge, UK) for 1 h at room tempera-
ture. After a ﬁnal PBS-T wash, the immunostained sections were
counterstained with DAPI (Sigma-Aldrich) and assessed with imaging
analysis software (NIS-Elements BR 3.0; Nikon, Tokyo, Japan) under a
ﬂuorescence microscope (Nikon).
2.4. RNA isolation and real-time polymerase chain reaction (PCR)
Total RNA was extracted and puriﬁed from kidney tissues using
the Trizol Reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer's protocol. The concentration and integrity of the iso-
lated RNA was spectrophotometrically measured using the
NanoDrop 1000 (Thermo Fisher Scientiﬁc, Wilmington, DE, USA).
The RNA (1 μg) was used as template to generate cDNA by reverse
transcription with the TaqMan Reverse Transcription Kit (Applied
Biosystems Inc., Foster City, CA, USA). The real-time PCR ampliﬁca-
tion reactions were carried out in 20 μl reactions, as follows: 10 μl
of TaqMan Universal PCR Master Mix (Promega, Madison, WI, USA),
1 μl of each primer, 3 μl of cDNA, and 6 μl double-deionized H2O.
The following primers were purchased from Life Technologies
Corporation (Carlsbad, CA, USA): p300 (Mm00625535_m1),
CBP (Mm01342452_m1), FN-1 (Mm01256744_m1) and GAPDH
(Mm99999915_g1). The reaction process was carried out in an ABI
7500 Real-Time PCR system (Applied Biosystems Inc.), using 40
ampliﬁcation cycles in a two-step cycling procedure (denaturation
at 95 °C for 15 s; annealing at 60 °C for 1 m). The comparative cycle
time (Ct) method was used to determine fold-differences between
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erence and relative to a calibrator (2−ΔΔCt).
2.5. Western blot assay
Unprocessed kidney tissues weremechanically homogenized in RIPA
lysis buffer and centrifuged (12,000 rpm at 4 °C) to remove cell debris.
The total proteins (supernatant) were collected and assessed by the
Bradford protein assay (Bio-Rad, Hercules, CA, USA) to measure the con-
centration before resolving by electrophoresis through a 10% SDS-PAGE
gel (at 110 V) and electrotransferring to a 0.22 mm polyvinylidene
diﬂuoride membrane. Any non-speciﬁc binding sites on the transferred
membrane were blocked by incubating in TBS containing 5% non-fat
milk and 0.5%BSA for 1 h at room temperature. Speciﬁc protein detection
was then carried out by incubating with the following primary antibod-
ies overnight at 4 °C: 1:1000 CTGF (sc-14939; Santa Cruz Biotechnology,
Dallas, TX, USA), 1:5000 PAI-1 (612024; BD Bioscience, San Jose, CA,
USA), 1:2000 H3K9/14Ac (9677s; Cell Signaling Technology), 1:1000
phosphorylated-JNK (9255s; Cell Signaling Technology), 1:1000 JNK
(9252; Cell Signaling Technology), and 1:3000 β-actin (sc-1616; Santa
Cruz Biotechnology). The membranes were then washed three times
with TBS containing 0.1% Tween-20 and incubated with the appropriate
horseradish peroxidase-conjugated secondary antibodies for 1 h at room
temperature. Immunoreactive bands were visualized by the enhanced
chemiluminescent substrate (Bio-Rad).
2.6. Histone acetyltransferase activity assay
HATs activity in kidney tissueswas quantiﬁed using the colorimetric
HATs Activity Assay Kit (Abcam) according to themanufacturer's proto-
col. Brieﬂy, the nuclear extractwas ﬁrst isolated from renal tissues using
a Nuclei Isolation Kit (Sigma-Aldrich) and 50 μg was then incubated
with HAT substrates I and II and the NADH-generating enzyme (in the
HAT assay buffer) at 37 °C for 1–4 h, depending on the color develop-
ment. The OD440nm was read at different times in a microplate reader
(Bio-Rad).Waterwas used as a negative control and control nuclear ex-
tracts provided by the manufacturer were used as the positive controls.
HATs' activity was expressed as the relative OD440nm value per micro-
gram per minute.
2.7. Chromatin immunoprecipitation (CHIP) assay
The ChIP assay was carried out using the EpiQuik™ Tissue ChIP Kit
(P-2003; Epigentek Group Inc., Farmingdale, NY, USA), following the
manufacturer's instructions. Brieﬂy, the assay wells were ﬁrst coated
with 2 μg of the speciﬁc antibody for a 90 min incubation at room tem-
perature. The following antibodieswere tested: H3K9/14Ac (9677s; Cell
Signaling Technology), p300 (sc-585x; Santa Cruz Biotechnology), and
CBP (7389s; Cell Signaling Technology). Negative and positive controls
were established with 1 μl of normal mouse IgG and anti-RNA polymer-
ase II, respectively. Meanwhile, 70 μg of kidney tissues were cut into
small pieces and cross-linked with 1% formaldehyde in PBS at room
temperature for 15–20 min. Glycine solution (1.25 M) was added to
stop the reaction. Tissue pieces were disaggregated and the nuclei
were isolated, after which the DNA was sheared by sonication using a
BransonDigital Soniﬁer (S-450-Dwithmicro-tip probe; Emerson Indus-
trial, St. Louis, MO, USA) with ﬁve pulses of 20 s each separated by 35 s
rest intervals. After centrifugation, 5 μl of the diluted supernatants were
removed for use as input DNA. The other 100 μl was transferred to the
antibody-coated wells and incubated at room temperature for 90 min.
ChIP-enriched DNA samples were collected and puriﬁed. ChIP-
enriched DNA and input DNA were analyzed by real-time PCR with
the following primers: CTGF forward 5′-GAGCTGAGTACATCATCTCAC-
3′, reverse 5′-GGACATTCAAGACATTCACAG-3′; PAI-1 forward 5′-CACC
AGGAGAGTCTGGCCCCATGT-3′, reverse 5′-ACTTCAAGTCCTTTCCTCCT
CCCT-3′; FN-1 forward 5′-GGAGTCGGACCGGACCC-3′, and reverse 5′-GTTGAGCCCCAAGAGCAGAG-3′. Data were analyzed relative to a cali-
brator (2−ΔΔCt) and normalized to input samples.2.8. Statistical analysis
Data were collected from four to ﬁve animals for each group and
presented as mean ± SD. ImageQuant 5.2 was used to analyze the
Western blotting results. OriginLab 7.5 data analysis and graphing soft-
ware were used to carry out comparisons between groups by one-way
ANOVA, followed by a Tukey's post hoc test. Statistical signiﬁcance was
considered if P b 0.05.3. Results
3.1. C66 prevented diabetes-induced renal dysfunction and hypertrophy
Body weight and blood glucose were recorded from 7 to 67 days
after STZ administration. We showed previously [32] that the body
weight and heart weight in the diabetic mice (DM) and DM + C66
was reduced. The C66 treatment also did not affect the blood glucose
proﬁle of diabetic mice.
Spot urinary albumin and urinary creatinine were measured. The
ACR was calculated as an index of renal function. At 3-months of treat-
ment (Fig. 1A), the ACR increased signiﬁcantly in DM relative to control.
After treatment with C66 for 3 months, the ACR was slightly (P N 0.05)
reduced. However, after treatment with JNKi for 3 months, the ACR
was signiﬁcantly reduced (P b 0.05). After 6months, the ACRwas signif-
icantly (P b 0.05) increased in DM compared to control mice (Fig. 1B).
The diabetic effect was signiﬁcantly (P b 0.05) reduced by the 3-
month C66 treatment, and only slightly reduced by the 3-month JNKi
treatment. It is known that serum creatinine levels often increase at
the late stages of DN. We observed signiﬁcantly (P b 0.05) increased
serum creatinine levels in DM that was signiﬁcantly (P b 0.05) reduced
by treatment with either C66 or JNKi (Fig. 1C).
Kidney weights were evaluated by examining the kidney weight
to tibia length ratio. There was no signiﬁcant difference for the ratio
of kidney weight to tibia length among groups after 3 months
(Fig. 1D). After 6 months (Fig. 1E), the kidney weight to tibia ratio
was signiﬁcantly (P b 0.05) increased in the DM group, but not
DM + C66 and DM + JNKi groups. This suggests that the diabetic
mice may have renal hypertrophy that is attenuated by C66 or
JNKi treatment. Taken together, these data showed that C66 and
JNKi act similarly to prevent the diabetic renal effect.3.2. C66 down-regulated diabetes-related activation of JNK after 3
months of treatment, but the affect was not sustained after treatment
stopped for 3 months
We next determined whether C66 has a direct effect on JNK activa-
tion under normal and diabetic conditions. Western blotting demon-
strated that phosphorylated JNK protein level was signiﬁcantly (P b
0.05) increased in the kidneys of the DMgroup compared to the control
group after 3 months and 6 months (Fig. 2A and B). Treatment of DM
with either C66 or JNKi signiﬁcantly decreased diabetic activation of
JNK (the ratio of p-JNK/JNK), which was observed after 3 months but
not 6 months (Fig. 2A and B). This ﬁnding suggests that C66 can signif-
icantly inhibit diabetic activation of JNK after treatment but does not
maintain this effect once treatment was ceased. The phosphorylation
level of c-jun, a downstream target of JNK, was measured to conﬁrm
the inhibitory effect of C66 on phosphorylated JNK. As expected, treat-
ment with either C66 or JNKi in DM signiﬁcantly (P b 0.05) decreased
phosphorylation c-jun protein levels (Fig. 2C). These ﬁndings suggest
that C66 can suppress the diabetic activation of JNK.
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Fig. 1. C66 prevented diabetes-induced renal functional changes. Spot urine and serum samples were collected from mice and the urinary albumin-to-creatinine ratio were determined
after (A) 3 months of treatment and (B) 6 months after treatment (equating to 3 months after treatment termination). The serum creatinine levels (C) were examined at the 6-month
period to determine renal function. Kidney weight was normalized to tibia length (D, 3 months; E, 6 months). Data are presented as mean ± SD after normalizing to control (n ≥ 4). *
P b 0.05 vs. control group; # P b 0.05 vs. DM group.
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Since JNKi can prevent diabetes-induced histological and biochemi-
cal changes, we determined the histological changes after C66 treat-
ment. Renal tissue staining with H&E (Fig. 3A) and Masson's trichrome
(Fig. 3B) revealed that diabetes induced a progressive increase in
mesangial cells and glomerular enlargement (Fig. 3A, B, C, E), which
was accompanied by progression of renal ﬁbrosis, the latter being evi-
denced by increased ECM with Masson's trichrome (blue) staining
(Fig. 3B, D, F). Both theC66 and JNKi treatments for 3months signiﬁcant-
ly attenuated the diabetes-induced glomerular enlargement and renal
ﬁbrosis.
The development of diabetes-induced renal ﬁbrosiswas further con-
ﬁrmed by examination of a few key proﬁbrotic cytokines, such as CTGF
and PAI-1, by Western blotting and real-time PCR. As shown in Fig. 4,the expression of CTGF and PAI-1 was signiﬁcantly increased in the kid-
neys of the DMmice, but not in the DM+ C66 nor the DM+ JNKi mice
at either the 3-month (Fig. 4A, B, G, H) or 6-month (Fig. 4C, D, I, J) time
point. When real-time PCR was used to examine the mRNA expression
of FN-1 in the kidney (Fig. 4E, F) it was found that administration of
C66 or JNKi signiﬁcantly prevented the diabetes-related up-regulation
of renal FN-1 mRNA expression at both the 3-month and 6-month
time point.
3.4. C66 prevented diabetic up-regulation of renal histone acetylation
through down-regulation of p300/CBP expression and HATs' activity
The above results showed that, similar to the JNKi treatment, the 3-
month C66 treatment of DM animals signiﬁcantly prevented diabetes-
related activation of renal JNK at the end of treatment, but the effect
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Fig. 2. C66 down-regulated diabetes-induced renal JNK pathway activity. Western blotting assay was performed to measure the expressions of phosphorylated-JNK and total JNK after
(A) 3 months of treatment and (B) 6 months after treatment (equating to 3 months after treatment termination). The downstream proteins, phoso-c-jun (p-c-jun) and c-jun, were
also measured at the 3-month time-point (C). The sample in each lane represents total proteins collected from each individual animal, and the data are presented as mean ± SD after
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(Fig. 2). In contrast, both the C66 and JNKi 3-month treatments signiﬁ-
cantly prevented diabetes-induced renal dysfunction (Fig. 1) as well as
the related histopathological changes, but these effects persisted out to
3 months after the treatments had been terminated. Diabetes itself
causes progressive biochemical and cellular changes in various organs,
a phenomenon known as the “metabolic memory effect” that involves
epigenetic mechanisms [35]. The persistent prevention of diabetes-
induced renal dysfunction and pathological changes provided by C66
and JNKi may also be related to epigenetic modulations. Since curcumin
is aHAT inhibitor and canprevent p300/CBP activation,we testedwheth-
er C66 can prevent diabetes-related histone hyperacetylation through
down-regulation of the expression and activation of HATs in the kidney.
The locations of acetylated histone H3K9/14Ac in the kidney tissueswere
assessed by Western blotting (Fig. 5A, B) and immunoﬂuorescent stain-
ing (Fig. 5C). The DM mice showed signiﬁcantly and progressively in-
creased expression of H3K9/14Ac, as compared with age-matched
controls, at both the 3-month and 6-month time points; however, the
DMmice treatedwith C66 or JNKi for 3months showed signiﬁcant atten-
uation of the diabetes-related increase in the expression of H3K9/14Ac
levels (Fig. 5A, 3 month study), which persisted through the 3 months
after the end of treatment (Figs. 5B, 6 month study). Moreover, the de-
tected expression of H3K9/14Ac was predominantly localized to the nu-
clei of both glomerular cells and renal tubular cells (Fig. 5C).To test whether C66 prevented the renal expression and activity of
HATs under the diabetic condition, real-time PCR was carried out to
measure the mRNA expression of p300 (Fig. 6A, B) and CBP (Fig. 6C,
D) in the kidney tissues and a colorimetric HAT activity assay was per-
formed to measure the HAT activity (Fig. 6E, F). The DM mice showed
signiﬁcantly increased expression and activity of HAT, as compared
with controls, at the 3-month time point, which persisted (without sig-
niﬁcant change) to the 6-month time point; however, treatment with
either C66 or JNKi for 3 months signiﬁcantly prevented the diabetes-
related up-regulation of HAT expression and activity, and these effects
lasted through the additional 3 months without treatment.
3.5. C66 prevented the diabetes-related increase in H3K9/14Ac level and
p300/CBP occupancy on the promoters of CTGF, PAI-1, and FN-1 gene
The results described above demonstrated that C66 can suppress
both total expression of H3K9/14Ac level and p300/CBP expression as
well as the activity in kidneys of DMmice, suggesting a functional rela-
tionship between histone acetylation and ﬁbrosis. Investigation of this
potential pathogenic process by CHIP assay, using the H3K9/14Ac anti-
body to examine the H3K9/14Ac levels on the gene promoters of CTGF
(Fig. 7A), PAI-1 (Fig. 7B) and FN-1 (Fig. 7C) in the kidney, showed that
the DMmice had signiﬁcantly increased levels for each, and that these
levels were similar for the C66- and JNKi-treated DM mice.
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Fig. 3. C66 prevented diabetes-induced renal structural changes. (A) Renal pathology shown by H&E staining. (B) Renal ﬁbrosis shown by Masson's Trichrome staining. Glomerular en-
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39Y. Wang et al. / Biochimica et Biophysica Acta 1852 (2015) 34–46The excessive histone acetylation at the CTGF, PAI-1 and FN-1 pro-
moters in DM mice suggested an association with p300/CBP activation,
which may be demonstrated by their occupancy at these genes' pro-
moters and indicate that C66 decreases the levels of histone acetylation
at these promoters by suppressing the recruitment of CBP and p300.
CHIP assay showed that the CTGF, PAI-1 and FN-1 gene promoter occu-
pancy by CBP (Fig. 7D, E, F) and p300 (Fig. 7G, H, I) was signiﬁcantlyincreased in DM kidneys. Both C66 and JNKi treatment signiﬁcantly
prevented the diabetes-related increased promoter occupancy of p300
and CBP for CTGF (Fig. 7D, G) and PAI-1 (Fig. 7E, H), and this effect lasted
through the additional 3 months of study following treatment termina-
tion. However, these C66- and JNKi-mediated preventive effects were
very moderate for the diabetes-related p300 and CBP occupancy at the
FN-1 promoter (Fig. 7F, I).
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Fig. 4. C66 prevented diabetes-induced renal ﬁbrosis.Western blotting assaywas used tomeasure the protein expression levels of the ﬁbrosis-related cytokines (A, C) CTGF and (B, D) PAI-1 in
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vs. DM group.
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In the present study, we demonstrated for the ﬁrst time that C66, a
novel curcumin analogue, can prevent diabetes-induced renal ﬁbrosis,Fig. 5. C66 prevented diabetes-induced renal histone acetylation. Expression of renal H3K9/14
(A, C) 3 months of treatment and (B, C) 6 months after treatment (equating to 3 months after
the nuclei (blue ﬂuorescence; DAPI staining) of both glomerular cells and renal tubular cells; or
(n ≥ 4). *P b 0.05 vs. control group; #P b 0.05 vs. DM group. Bar: 50 μm.and the subsequent renal dysfunction, in STZ-induced diabetic mice
by down-regulating the p300/CBPHAT expression and total HAT activa-
tion via suppression of JNK activation; this process is summarized in
Fig. 8.was measured by (A, B) Western blotting assay and (C) immunoﬂuorescence staining at
treatment termination). In panel C, H3K9/14 is shown as present (green ﬂuorescence) in
iginal magniﬁcation: ×200. Data are presented asmean ± SD after normalizing to control
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Fig. 7.C66produced a persistent decrease in the diabetes-induced increase in renal H3K9/14 levels on thepromoters of CTGF, PAI-1 and FN-1 genes. CHIP assaywasused to detect the (A, B,
C) H3K9/14 levels and (D, E, F) p300 occupancy on the (A) CTGF, (B) PAI-1 and (C) FN-1 promoters at 6 months after treatment (equating to 3months after treatment termination). Nor-
mal mouse IgG was used as a negative control and data were normalized to input DNA samples. n = 5; *P b 0.05 vs. control group; #P b 0.05 vs. DM group.
43Y. Wang et al. / Biochimica et Biophysica Acta 1852 (2015) 34–46The “metabolic memory” phenomenon, in which a previous expo-
sure to hyperglycemia is associated with progression of diabetic vascu-
lar complications despite achievement of good glycemic control [35],
may involve epigenetic modulation of chromatin [36–38]. As described
in the introduction, accumulation of ECM and development of renal ﬁ-
brosis can cause DN, and proﬁbrotic cytokines (such as CTGF, PAI-1
and FN-1) play key roles in the progression of renal ﬁbrosis to DN [3,
4]. In the present study, DMmicewere observed to have signiﬁcantly in-
creased ACR and serum creatinine level at 3 and 6 months after the dis-
easemodelwas established, with H&E andMasson's Trichrome staining
showing renal pathological changes corresponding to the disease-
related aberrations. In addition, these changes were found to beassociated with signiﬁcant increases in the expression of the ﬁbrous cy-
tokines, CTGF, PAI-1 and FN-1, in the diabetic kidney.
Histone acetylation is an important post-transcriptional modiﬁ-
cation of histones that leads to the recruitment of protein
complexes/transcription factors essential for gene expression and
its proper regulation. The p300/CBP complex has been extensively
studied and characterized as an important HAT subtype for gene ex-
pression in general [39]. Recent studies have indicated that both the
p300/CBP complex and histone acetylation modiﬁcations contribute
to the development and persistence of diabetes and its complica-
tions. In particular, experiments using cultured monocytes showed
that exposure to high glucose (hyperglycemic) conditions led to
Diabetes
p-JNK
p300/CBP
C66
HATs acvaon
CBPH3
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H3
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p300
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FN1
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Renal ﬁbrosis
Glomerulosclerosis
Renal dysfuncon
JNKi
Fig. 8. Schematic illustration of the protectivemechanismof C66 against diabetes-induced
renal ﬁbrosis and progression of DN. The mechanism involves inhibition of activation of
the JNK pathway via epigenetic modulation of p300/CBP-mediated histone acetylation.
In the kidneys of the STZ-induced diabetic mouse model, the JNK-induced activation of
p300/CBP HATs promotes histone lysine acetylation at target gene promoters, such as
CTGF, PAI-1 and FN-1, as well as the occupancy of p300/CBP on the promoters of these
genes. These events can enhance the expression of CTGF, PAI-1 and FN-1 genes, resulting
in renal ﬁbrosis and glomerulosclerosis, both of which are involved in DN pathogenesis.
C66 can prevent these changes through its effects on the JNK pathway and histone acety-
lation. Curcumin, for which C66 analogue is the analogue, is an inhibitor of p300/CBP, but
whether curcumin can inhibit the p300/CBP complex's expression, activation or function
remains unknown.
44 Y. Wang et al. / Biochimica et Biophysica Acta 1852 (2015) 34–46activation of CBP and increased histone H3 acetylation, culminating
in up-regulated expression of genes with inﬂammation-related
functions [40]. Results from related in vivo studies conﬁrmed that
the increased histone acetylation can lead to inﬂammatory gene
transcription under diabetic conditions [40]. Moreover, data from a
clinical trial suggested that elevated acetylated histone levels play
an important role in both vascular injury and remodeling in Type 1
diabetes [41]. Similar to these collective ﬁndings, our study of the
STZ-induced diabetes mouse model showed that the diabetic condi-
tion was associated with signiﬁcant increases in total HAT activity
and H3K9/14Ac level. Treating these diabetic mice with C66 led to
signiﬁcant decreases in the diabetes-related elevations in p300/
CBP occupancy in the promoters of the CTGF, PAI-1 and FN-1,
which ultimately led to decreased H3K9/14Ac level and CTGF, PAI-
1 and FN-1 gene expression. Therefore, the renal protective property
of C66 in diabetes may involve its ability to suppress HAT activity.
As a p300 inhibitor, curcumin can prevent p300-mediated HAT
events. In cardiac myocytes, curcumin has been shown to down-
regulate gene expression reducing histone acetylation [42]. In a previ-
ous study of diabetes, curcumin was shown to prevent high glucose
that was otherwise induced by p300 mRNA up-regulation and protein
production that increases acetylation levels in endothelial cells [19].
Similarly, in the present study we demonstrated that the curcumin an-
alogue, C66, effectively protected against pathogenic events in diabetes
by decreasing the diabetes-related enhancement of p300/CBP mRNA
expression, HATs' activation, andH3K9/14Ac levels in the kidney.More-
over, immunoﬂuorescence staining showed increased H3K9/14Ac inthe diabetic kidney, the expression of which was localized to the nuclei
of both glomerular cells and renal tubular cells. To further understand
the regulation of histone acetylation mediated by cytokines related to
renal ﬁbrosis, speciﬁcally CTGF, PAI-1 and FN-1, we investigated the
levels of H3K9/14Ac and p300/CBP occupancy at the promoters of
these genes after 6 months of the diabetic model being established.
While the diabetic condition was associated with increased level of
H3K9/14Ac and p300/CBP occupancy at these genes' promoters in the
kidney, the treatment with C66 and JNKi resolved these aberrations.
Another important and novel ﬁnding of the present study is that C66
renal protection ismediated by inactivation of JNK. It has been previous-
ly shown that the JNK pathway can be activated by high glucose, with
the subsequent up-regulated expression of ﬁbrosis cytokines and pro-
motion of renal ﬁbrosis [14]. Since our previous study also showed the
relatedness of JNK inactivation and C66 prevention of diabetic renal
damage, a group of diabetic mice treated with JNKi was included in
the present study to conﬁrm that JNK activation is a pivotal mediator
of diabetic renal ﬁbrosis and the eventual development of DN. Our stud-
ies of these JNKi-treated DMmice provided similar results to those ob-
served in the C66-treated DMmice. Activation of the JNK pathway can
regulate recruitment of p300 and enhancement of histones H3 and H4
acetylation [43]. Accordingly, we concluded that the C66 treatment of
diabetic mice down-regulates diabetes-increased p300/CBP expression
and HATs activation via inactivation of JNK, and the subsequent histone
hyperacetylation causes speciﬁc increases in the accumulation of p300/
CBP at the promoters of CTGF, PAI-1 and FN-1 genes, as presented in
Fig. 8.
Thus, we report here for the ﬁrst time that C66 can act as a strong
preventive agent against diabetes-induced renal ﬁbrosis and renal inju-
ry in the STZ-induced mouse model of diabetes through down-
regulation of JNK pathway activation. More importantly, investigations
of these mice at 3 months after the treatment had been terminated
showed that neither the C66 treatment nor the JNKi treatment could
suppress the diabetes-related stimulation of JNK phosphorylation.
However, the C66- and JNKi-mediated prevention of diabetes-induced
renal dysfunction and structure changes and increased expression of ﬁ-
brosis cytokines persisted through 3 additional months after the treat-
ments had been terminated. Diabetes-related activation of the JNK
pathway in the kidney via epigenetic mechanisms, and the subsequent
up-regulation of renalﬁbrotic signaling are prevented byC66 treatment,
in this study by a 3-month treatment course. The persistence of these
C66 protective effects may be related to the ability of C66 to suppress
p300/CBP activation via long-term epigenetic modiﬁcations, which
may affect the “metabolic memory” that may underlie the diabetic con-
dition [44,45]. Therefore, the present study provides the ﬁrst evidence
to support early application of C66 to prevent diabetes-induced renal
early activation of JNK and the consequent p300/CBP expression and
HAT activation via epigenetic mechanisms; in essence, C66 may
represent a therapeutic approach to provide a “protective memory,” fa-
cilitating sustained renal protection from diabetes even 3 months after
the end of treatment.
In summary, our study provides extensive evidence that diabetes ac-
tivates the JNK pathway, which in turn induces an epigenetic mecha-
nism via stimulation of p300/CBP expression and HATs' activation,
subsequently increasing the transcription of ﬁbrotic genes, such as
CTGF, PAI-1 and FN-1. Ultimately, these molecular events promote
renal ﬁbrosis and kidney dysfunction.Moreover, C66 can provide an en-
during renal protective effect through its down-regulation of the JNK
pathway and induction of epigenetic changes, providing a “renal protec-
tive memory.” Another important insight provided by this study is that
the JNK pathway and HATs, as well as histone acetylation, may repre-
sent a novel therapeutic strategy by which to combat the development
of diabetic complications; considering that C66 is a curcumin analogue,
with signiﬁcant efﬁcacy at lower doses than the plant compound
curcumin, C66 holds particular promise for clinical application to dia-
betic patients, especially for prevention of DN. Future studies are
45Y. Wang et al. / Biochimica et Biophysica Acta 1852 (2015) 34–46warranted to study the efﬁcacy and safety of this potential therapeutic
agent in humans.
There are some limitations inherent to the design of the present
study, which must be considered when interpreting our ﬁndings. First,
a high dose of STZ (used to establish our diabetic mouse model) may
be cytotoxic to kidneys, due to its tubular toxicity, which may occlude
distinguishing DN-related neuropathy from STZ-induced nephropathy
[46,47]. Even though we used a high dose of STZ (delivered as a single
intraperitoneal injection of 150 mg/kg) to establish the diabetic
model, our investigations were carried out at 3 and 6 months after the
STZ administration; this strategyminimized the potential role of tubular
toxicity, but did not eliminate it. Establishing the model by using a re-
peated injection of low dose STZ (50 mg/kg/day × 5 days) would have
been more appropriate [48], and future studies should consider this
modeling approach. Second, the STZ-induced diabetes model was
established in C57BL/6J mice in the present study. It is important to
note that, although C57BL/6J mice are valuable tools for studying diet-
induced obesity, hyperglycemia and hyperinsulinemia, these mice ex-
hibit very limited features of DN [49]. Therefore, the use of a mouse
strain with more DN susceptibility, such as 129 SvEv mice [50], may
be preferable and may reveal more information regarding the C66-
and/or JNK-mediated prevention of the early and late features of DN.
In addition, although we have clearly indicated the predominant role
of the JNK pathway in the development of DN, and its prevention by
C66 and JNKi, it remains unknownwhether other pathways are affected
by these drugs.
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